2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.
Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.
The checkpoint inhibitors are how the body recognizes itself, explains Lallas. Checkpoint inhibitors allow T cells to be activated, and increase cellular response against malignancies, which is a reason why immunotherapy has been efficacious.
Hypothetically, if you can combine regimens that ramp up the immune system maximally to fight these malignancies, it is going to be beneficial, states Lallas.
Related Content: